A randomized placebo-controlled trial of idebenone in Leber’s hereditary optic neuropathy.
Open accessThe DOI matches its Crossref record; 30 of the 32 references it cites were found in a registry or an index.
Abstract
Major advances in understanding the pathogenesis of inherited metabolic disease caused by mitochondrial DNA mutations have yet to translate into treatments of proven efficacy. Leber's hereditary optic neuropathy is the most common mitochondrial DNA disorder causing irreversible blindness in young adult life. Anecdotal reports support the use of idebenone in Leber's hereditary optic neuropathy, but this has not been evaluated in a randomized controlled trial. We conducted a 24-week multi-centre double-blind, randomized, placebo-controlled trial in 85 patients with Leber's hereditary optic neuropathy due to m.3460G>A, m.11778G>A, and m.14484T>C or mitochondrial DNA mutations. The active drug was idebenone 900 mg/day. The primary end-point was the best recovery in visual acuity. The main secondary end-point was the change in best visual acuity. Other secondary end-points were changes in visual acuity of the best eye at baseline and changes in visual acuity for both eyes in each patient. Colour-contrast sensitivity and retinal nerve fibre layer thickness were measured in subgroups. Idebenone was safe and well tolerated. The primary end-point did not reach statistical significance in the intention to treat population. However, post hoc interaction analysis showed a different response to idebenone in patients with discordant visual acuities at baseline; in these patients, all secondary end-points were significantly different between the idebenone and placebo groups. This first randomized controlled trial in the mitochondrial disorder, Leber's hereditary optic neuropathy, provides evidence that patients with discordant visual acuities are the most likely to benefit from idebenone treatment, which is safe and well tolerated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therapy for LHON has been restricted to supportive measures rather than cure.10”
From Immune Response and Intraocular Inflammation in Patients With Leber Hereditary Optic Neuropathy Treated With Intravitreal Injection of Recombinant Adeno-Associated Virus 2 Carrying the ND4 Gene: A Secondary Analysis of a Phase 1/2 Clinical Trial (2019) · cites this paper as [10]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Current treatments for LHON remain inadequate.8 Idebenone (Raxone, Santhera GmbH) was granted market authorization by the European Medicines Agency (EMA) for the treatment of LHON under exceptional circumstances, 9,10 but its benefits are limited.”
From Efficacy and Safety of Intravitreal Gene Therapy for Leber Hereditary Optic Neuropathy Treated within 6 Months of Disease Onset (2021) · cites this paper as [10]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1976) · Medical Entomology and Zoology · Cited by 8,899
Linear Mixed Models for Longitudinal Data
Verbeke, G. (1997) · Lecture Notes in Statistics · doi:10.1007/978-1-4612-2294-1_3 · Cited by 3,506
(2025) · Springer Reference Medizin · doi:10.1007/978-3-662-65186-5_300379 · Cited by 1,445
Linear mixed models for longitudinal data
(2000) · Springer Series in Statistics · doi:10.1007/b98969 · Cited by 818
Lange, C., Feltgen, N., Junker, B., Schulze-Bonsel, K., & Bach, M. (2009) · Graefe's Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-008-0926-0 · Cited by 626 · cited 1×
“Patients only able to count fingers, detect hand motion or light perception were assigned logMAR values 2.0, 2.3 and 2.6, respectively (Lange et al., 2009).”
BackgroundInfluentialRiordan-Eva, P., Sanders, M. D., Govan, G. G., Sweeney, M. G., Costa, J. D., & Harding, A. E. (1995) · Brain · doi:10.1093/brain/118.2.319 · Cited by 490
The Epidemiology of Leber Hereditary Optic Neuropathy in the North East of England
Man, P. Y. W., Griffiths, P. G., Brown, D. T., Howell, N., Turnbull, D. M., & Chinnery, P. F. (2003) · The American Journal of Human Genetics · doi:10.1086/346066 · Cited by 483 · cited 1×
“Leber’s hereditary optic neuropathy (LHON; MIM 535000) is the most common mitochondrial disorder affecting more than 1:14 000 males (Man et al., 2003).”
BackgroundSelf-citationNewman, N. J., Lott, M. T., & Wallace, D. C. (1991) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(14)76784-4 · Cited by 403 · cited 3×
“Most remain legally blind, are unable to drive a motor vehicle, and are unable to find employment (Newman et al., 1991; Riordan-Eva et al., 1995; Nikoskelainen et al., 1996).”
BackgroundResultInfluentialThe epidemiology of mitochondrial disorders—past, present and future
Schaefer, A. M., Taylor, R. W., Turnbull, D. M., & Chinnery, P. F. (2004) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2004.09.005 · Cited by 396 · cited 1×
“Inherited disorders of mitochondrial energy metabolism are a major cause of metabolic disease affecting more than 1/5000 of the population (Schaefer et al., 2004).”
BackgroundSelf-citationBARBONI, P., SAVINI, G., VALENTINO, M., MONTAGNA, P., CORTELLI, P., DENEGRI, A., SADUN, F., BIANCHI, S., LONGANESI, L., & ZANINI, M. (2005) · Ophthalmology · doi:10.1016/j.ophtha.2004.06.034 · Cited by 247 · cited 14×
“Leber’s hereditary optic neuropathy (LHON; MIM 535000) is the most common mitochondrial disorder affecting more than 1:14 000 males (Man et al., 2003).”
BackgroundInfluential
Research works printed but not linked: 1
- Harding AE Sweeney MG Govan GG Riordan-Eva P Pedigree analysis in Leber hereditary optic neuropathy families with a pathogenic mtDNA mutation Am J Hum Genet 1995 57 77 86 7611298 PMC1801226
Cited by
Items 301–400 of 574
Progress in diagnosis and treatment of Leber’s hereditary optic neuropathy
Ma, Q., Sun, Y., Lei, K., & Luo, W. (2023) · Journal of Molecular Medicine · doi:10.1007/s00109-023-02389-2 · Cited by 6
“It is the only drug that has been proven effective through clinical research [25].”
Jørstad, Ø. K., Ødegaard, E. M., Heimdal, K., & Kerty, E. (2017) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0000000000000598 · Cited by 7
Bušányová, B., Vajter, M., Kelifová, S., Lišková, P., Miková, H., Breciková, K., Zigmond, J., Rogalewicz, V., Tichopád, A., Višňanský, M., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e32296 · Cited by 6
Uittenbogaard, M. N., & Chiaramello, A. (2020) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2020.06.011 · Cited by 6
Mercuț, M. F., Tănasie, C. A., Dan, A. O., Nicolcescu, A. M., Ică, O. M., Mocanu, C. L., & Ştefănescu-Dima, A. (2022) · Romanian Journal of Morphology and Embryology · doi:10.47162/rjme.63.1.24 · Cited by 6
Clinical trials in mitochondrial diseases
Karaa, A., & Klopstock, T. (2023) · Handbook of clinical neurology · doi:10.1016/b978-0-12-821751-1.00002-6 · Cited by 8
Self-citationBuonfiglio, P. I., Menazzi, S., Francipane, L., Lotersztein, V., Ferreiro, V., Elgoyhen, A. B., & Dalamón, V. (2023) · PLoS ONE · doi:10.1371/journal.pone.0275703 · Cited by 7
Neuro-ophthalmology in Medicine
Eggenberger, E., & Pula, J. H. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-407710-2.00024-2 · Cited by 6
Kurimoto, T., Ueda, K., Mori, S., Sakamoto, M., Yamada‐Nakanishi, Y., Matsumiya, W., & Nakamura, M. (2019) · Clinical ophthalmology · doi:10.2147/opth.s204669 · Cited by 7
Metabolic Stability of New Mito-Protective Short-Chain Naphthoquinones
Feng, Z., Smith, J. A., Gueven, N., & Quirino, J. P. (2020) · Pharmaceuticals · doi:10.3390/ph13020029 · Cited by 6
Coenzyme Q10: Role in Less Common Age-Related Disorders
Mantle, D., & Hargreaves, I. P. (2022) · Antioxidants · doi:10.3390/antiox11112293 · Cited by 6
Oxford Handbook of Clinical Specialties
(2020) · doi:10.1093/med/9780192888501.001.0001 · Cited by 6
Psychometric Validity of the Visual Function Index in Leber Hereditary Optic Neuropathy
Chen, B. S., Yu‐Wai‐Man, P., & Horton, M. (2023) · Translational Vision Science & Technology · doi:10.1167/tvst.12.1.23 · Cited by 5
Self-citationLeber’s hereditary optic neuropathy: Update on the novel genes and therapeutic options
Hu, J., Hsu, C., Hsiao, Y., Lin, Y., Lai, W., Liu, Y., Wang, C.-L., Ko, Y., Tsai, M., Tseng, H., et al. (2023) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000001031 · Cited by 5
“18 Based on the results of this clinical trial, idebenone was approved in Europe in 2015 and is now widely used in LHON treatment.”
Hereditary Optic Neuropathies: An Updated Review
Lee, S., Mura, C., Abreu, N. J., Rucker, J. C., Galetta, S. L., Balcer, L. J., & Grossman, S. N. (2024) · Journal of Clinical & Translational Ophthalmology · doi:10.3390/jcto2030006 · Cited by 8
“Secondary endpoints of change in best visual acuity (better eye at baseline to better eye at study end) and change in visual acuity for both eyes were statistically significant in favor of the idebenone group [45].”
BackgroundMethodIdebenone treatment in Leber's hereditary optic neuropathy: rationale and efficacy
Gueven, N., & Faldu, D. (2013) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2013.772894 · Cited by 6
“Following a number of earlier case studies [49-55], two recent studies [56,57] provide more convincing clinical evidence that idebenone can positively influence disease pathology (Table 2).”
BackgroundResultLeo‐Kottler, B., & Wissinger, B. (2011) · Der Ophthalmologe · doi:10.1007/s00347-011-2482-y · Cited by 5
Anatomy of the Optic Nerve and Visual Pathway
Lee, A. G., Morgan, M. L., Palau, A. E. B., Mai, C. K., Chen, Y., Soeken, T. A., Choudhury, E. A., & Yari, N. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-410390-0.00020-2 · Cited by 13
Raxone dans la neuropathie optique de Leber : retour d’expérience parisienne
Orssaud, C., Bidot, S., Lamirel, C., Brémond‐Gignac, D., Touitou, V., & Vignal‐Clermont, C. (2019) · Journal Français d Ophtalmologie · doi:10.1016/j.jfo.2018.06.010 · Cited by 5
Development of a 3D Printed Neuroanatomy Teaching Model
Bialy, S. E., Weng, R., & Jalali, A. (2019) · University of Ottawa Journal of Medicine · doi:10.18192/uojm.v9i1.4057 · Cited by 5
Rizk, M., Dunya, I., Seif, R., Mégarbané, A., & Sadaka, A. (2022) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0000000000001665 · Cited by 5
Comparative In Vitro Toxicology of Novel Cytoprotective Short-Chain Naphthoquinones
Feng, Z., Sedeeq, M., Daniel, A., Corban, M., Woolley, K. L., Condie, R., Azimi, I., Smith, J. A., & Gueven, N. (2020) · Pharmaceuticals · doi:10.3390/ph13080184 · Cited by 6
“The only drug currently available to patients is benzoquinone idebenone, which protects against vision loss and has even restored visual acuity in some LHON patients [18].”
BackgroundLeber’s hereditary optic neuropathy: new quinone therapies change the paradigm
Sadun, A. A., Morgia, C. L., & Carelli, V. (2012) · Expert Review of Ophthalmology · doi:10.1586/eop.12.27 · Cited by 6
Advances in Management of Mitochondrial Myopathies
Bangeas, A., Poulidou, V., Liampas, I., Marogianni, C., Aloizou, A., Tsouris, Z., Sgantzos, M. N., Arnaoutoglou, M., Bogdanos, D. P., Dardiotis, E., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115411 · Cited by 12
“Idebenone, which is a synthetic analog of CoQ10 approved in Europe for the management of visual impairment in LHON, was initially tested in a randomized placebo-controlled trial of LHON patients [101].”
Mitochondrial dysfunction in neurodegenerative disorders: mechanisms and therapeutic advances
Tong, Y., He, J. N., Zhou, L., Zhang, J., Ho, B. M., Du, L., Yip, Y. W. Y., Bisnauthsing, H., Chan, P. P. M., Tham, C. C. Y., et al. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00480-x · Cited by 6
“A multi-center, randomized clinical trial in 85 LHON patients experiencing vision loss within five years provided evidence that individuals with more recent onset of vision loss and discordant visual acui-ties are more likely to benefit from Idebenone treatment [136].”
Mitochondrial Activation and Therapeutics: Innovations in Cell- and Organelle-Specific Medicine
Sato, I., Shiraishi, M., Norota, K., Shiraki, K., & Yamada, Y. (2025) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b25-00218 · Cited by 9
Sadun, A. A. (2013) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0b013e31829343a0 · Cited by 4
Mitochondrial Dysfunction and Myoclonic Epilepsy
Frye, R. E. (2011) · Journal of Child Neurology · doi:10.1177/0883073811420720 · Cited by 4
Afaf, E. A., Ghada, A. S., & Abeer, A. D. (2013) · AFRICAN JOURNAL OF BIOTECHNOLOGY · doi:10.5897/ajb12.2880 · Cited by 4
Analysis of clinical features of tacrolimus‐induced optic neuropathy
Lei, H., Zeng, J., Liu, X., Li, Z., & Wang, C. (2022) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13658 · Cited by 4
Madden, R. F., Lalonde-Bester, S., Parnell, J. A., Trudeau, M. S., Martin, J. M., Khan, A., & Shearer, J. (2022) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2022.06.016 · Cited by 4
Genetische Ursachen und genetische Diagnostik bei hereditären Optikusatrophien
Wissinger, B. (2018) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/a-0759-2094 · Cited by 4
Current and Emerging Therapies for Mitochondriopathies
Lagler, F. B. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_264 · Cited by 4
Liutkevičienė, R., Sidaraitė, A., Kuliaviene, L., Glebauskienė, B., Jurkutė, N., Aluzaite-Baranauskiene, L., Gelžinis, A., & Žemaitienė, R. (2021) · Medicina · doi:10.3390/medicina57030202 · Cited by 5
Carey, A. R. (2021) · Springer eBooks · doi:10.1007/978-3-030-74103-7_9 · Cited by 4
Ocular Manifestations of Inborn Errors of Metabolism
Ganesh, A., Al-Murshedi, F., Al-Zuhaibi, S. S., & Al‐Thihli, K. (2017) · Springer eBooks · doi:10.1007/978-3-319-18389-3_13 · Cited by 6
Ahmadi, Z. A., & Brandt, U. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2025.167996 · Cited by 6
Hu, C., Su, T., Zhang, Y., Yang, J. F., Su, X. J., Zhang, Z., Wang, X., Zou, W., Liang, D., Liu, Y., et al. (2025) · Cellular Signalling · doi:10.1016/j.cellsig.2025.112121 · Cited by 3
Advanced therapies for inherited optic neuropathies
Wong, D., Makam, R., & Yu‐Wai‐Man, P. (2025) · Eye · doi:10.1038/s41433-025-04109-1 · Cited by 6
“Idebenone was well-tolerated with a favourable safety profile similar to previous studies [21, 23].”
Self-citationNew Insights on Mitochondria-Targeted Neurological Drugs
Lores‐Arnaiz, S. (2026) · Biology · doi:10.3390/biology15030228 · Cited by 4
Mitochondrial Encephalomyopathies
Vivo, D. C. D., Paradas, C., & DiMauro, S. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-417044-5.00041-x · Cited by 3
A challenging differential diagnosis - Leber’s Hereditary Optic Neuropathy
Iorga, R. E., Dănulescu, R. M., & Danielescu, C. (2024) · Romanian Journal of Ophthalmology · doi:10.22336/rjo.2024.13 · Cited by 3
“The results showed a consistent positive trend in treated patients compared to controls, whose VA deteriorated [ 26 ].”
ResultIsolated and Syndromic Genetic Optic Neuropathies: A Review of Genetic and Phenotypic Heterogeneity
Zeppieri, M., Gagliano, C., Maita, M. D., Avitabile, A., Gagliano, G., Dammino, E., Tognetto, D., Cordeiro, M. F., & D’Esposito, F. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26083892 · Cited by 4
“It is indicated for the treatment of adolescents and adults affected by LHON at a daily dose of 900 mg [26–28].”
InfluentialMolecular mechanisms and pathogenetic treatment of mitochondrial optic neuropathies
Nevinitsyna, T. A., & Sheremet, N. L. (2016) · Russian Annals of Ophthalmology · doi:10.17116/oftalma2016132191-96 · Cited by 4
“В ходе окислительно-восстановительных реакций, или окислительного фосфорилирования (ОФ), электроны передаются по 4 комплексам (I — NADH-CoQредуктаза, II — сукцинатдегидрогеназа, III — CoQН2цитохром С-редуктаза, или комплекс bс1, IV — цитохром С-оксидаза) с участием 2 молекул-переносчиков (убихинона, или коэнзима Q, и…”
InfluentialMitochondrial Medicine: A Historical Point of View
Ng, Y. S., DiMauro, S., & Turnbull, D. M. (2019) · Springer eBooks · doi:10.1007/978-3-030-05517-2_1 · Cited by 3
Ji, X., Khdour, O. M., & Hecht, S. M. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0481 · Cited by 3
14th EUNOS Congress: PORTO, PORTUGAL, 16–19 JUNE 2019
Liutkevičienė, R., Glebauskienė, B., Sidaraitė, A., & Jurkutė, N. (2019) · Neuro-Ophthalmology · doi:10.1080/01658107.2019.1608780 · Cited by 3
Aung, M. H., Volpe, N. J., Choi, D., Stein, J. M., Goldstein, A., & Liu, G. T. (2022) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0000000000001651 · Cited by 3
Major, T. C., Arany, E. S., Schon, K. R., Simó, M., Karcagi, V., van den Ameele, J., Yu‐Wai‐Man, P., Chinnery, P. F., Olimpio, C., & Horváth, R. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1292320 · Cited by 3
Self-citationTahmasebi, M., Cugati, S., & Chen, C. (2025) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.14544 · Cited by 2
“Early diagnosis may serve useful in light of evolving therapeutic options available for LHON [102, 103].”
Never too old: late‐onset Leber hereditary optic neuropathy
Vincent, S. J., Lowe, K. A., & Monsour, C. S. (2017) · Clinical and Experimental Optometry · doi:10.1111/cxo.12530 · Cited by 3
Leber’s hereditary optic neuropathy
Cherninkova, S. (2017) · Bulgarian Review of Ophthalmology · doi:10.14748/bro.v0i2.4514 · Cited by 3
Bénit, P., Schiff, M., Cwerman‐Thibault, H., Corral‐Debrinski, M., & Rustin, P. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2016.1117972 · Cited by 4
Gene-Based Therapies for Leber Hereditary Optic Neuropathy. Hype or Hope?
Mackey, D. A., Kearns, L. S., & Hewitt, A. W. (2016) · Asia-Pacific Journal of Ophthalmology · doi:10.1097/apo.0000000000000220 · Cited by 3
“A large randomized trial, Rescue of Hereditary Optic Disease Outpatient Study, enrolled 85 patients with a confirmed primary mtDNA mutation and with disease duration of up to 5 years.(9) Patients treated with idebenone (900 mg/d) experienced no adverse drug reactions over 24 weeks.”
BackgroundSevere sequential visual loss in MS co-diagnosis of Leber's hereditary optic neuropathy
Riccio, P. M., Fraser, J. A., Lee, D. H., & Morrow, S. A. (2018) · Canadian Journal of Ophthalmology · doi:10.1016/j.jcjo.2018.06.020 · Cited by 3
Clinical Updates and Recent Developments in Neuro-Ophthalmology
Vuppala, A.-A. D., & Miller, N. R. (2019) · Springer eBooks · doi:10.1007/978-3-030-25389-9_8 · Cited by 3
Further advances in the diagnosis and treatment of Leber’s Hereditary Optic Neuropathy – a review
Tăbăcaru, B., & Stanca, H. T. (2022) · Romanian Journal of Ophthalmology · doi:10.22336/rjo.2022.4 · Cited by 4
Mitochondrial Disorders Due to Mutations in the Nuclear Genome
Chinnery, P. F. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-410529-4.00024-3 · Cited by 3
Self-citationCatarino, C. B., von Livonius, B., Priglinger, C., Landau, K., Newman, N. J., Votruba, M., Rudolph, G., & Klopstock, T. (2021) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0000000000001318 · Cited by 3
Self-citationRibeiro, P. V. Z., Mitre, L. P., Gauza, M. D. M., Furukawa, P. H., Ferraz, V. E. D. F., & Gomy, I. (2025) · Ophthalmic Genetics · doi:10.1080/13816810.2025.2521647 · Cited by 2
“This was first seen in a number of case reports/series and cohorts (7), further supported by the Rescue of Hereditary Optic Disease Outpatient (RHODOS) study (8), the first randomized controlled trial (RCT) on the subject.”
InfluentialTechnological advances in the diagnosis and management of inherited optic neuropathies
Britton, J. O. T., Yu‐Wai‐Man, P., & Chen, B. S. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1609033 · Cited by 4
“…approved by the European Medicines Agency for use in LHON in 2015 following results from the RHODOS and RHODOS-OFU trials, as well as an industry-sponsored expanded access programme, which demonstrated the effectiveness of idebenone in LHON patients treated within 1 year of symptom onset (49–51).”
Self-citationOrssaud, C., & Reynier, P. (2025) · Metabolomics · doi:10.1007/s11306-025-02328-x · Cited by 2
“Idebenone, an analog of coenzyme Q10, is the most commonly used treatment (Carelli et al., 2017 ; Klopstock et al., 2011).”
Aoshima, K., Takagi, Y., Funato, M., Kuse, Y., Nakamura, S., & Shimazawa, M. (2025) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2025.1635775 · Cited by 2
Sanders, F., & Votruba, M. (2025) · Eye · doi:10.1038/s41433-025-03993-x · Cited by 3
“Additionally, this includes those who may not benefit from idebenone because they have already experienced some spontaneous improvement or partial recovery of visual function, as was observed with approximately 30–40% of individuals within LHON in previous trials of idebenone [3, 13, 18, 19].”
InfluentialPanusatid, C., Soiyangsuk, R., Tanadjindarat, M., & Peerapittayamongkol, C. (2025) · FEBS Open Bio · doi:10.1002/2211-5463.70165 · Cited by 2
“Clinical trials have substantiated its benefit in visual recovery, especially when administered early in disease progression [71,72].”
Brodsky, M. C. (2009) · Springer eBooks · doi:10.1007/978-0-387-69069-8_4 · Cited by 2
Complex Subunits and Assembly Genes: Complex I
Saada, A. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3722-2_12 · Cited by 2
Therapies Approaches in Mitochondrial Diseases
Emmanuele, V., Quinzii, C. M., & Hirano, M. (2021) · Springer eBooks · doi:10.1007/978-3-030-70147-5_11 · Cited by 3
Traitements médicaux dans la neuropathie optique héréditaire de Leber
Hage, R. (2022) · Journal Français d Ophtalmologie · doi:10.1016/s0181-5512(22)00447-8 · Cited by 3
Mitochondrial disease in neurology—Past, present, and future
Chinnery, P. F. (2023) · Handbook of clinical neurology · doi:10.1016/b978-0-12-821751-1.00001-4 · Cited by 2
Self-citationSchworm, B., Siedlecki, J., Catarino, C. B., von Livonius, B., Muth, D. R., Rudolph, G., Havla, J. B., Klopstock, T., & Priglinger, C. (2023) · European Journal of Neurology · doi:10.1111/ene.15847 · Cited by 2
“Idebenone has been shown to positively affect the disease course in terms of visual acuity recovery when compared to the natural course of the disease in adults [14,15].”
BackgroundSelf-citationQuigley, C., Stephenson, K. A. J., Kenna, P. F., & Cassidy, L. (2024) · BMJ Open Ophthalmology · doi:10.1136/bmjophth-2023-001295 · Cited by 2
Leber’s hereditary optic neuropathy
Takai, Y., Yamagami, A., & Ishikawa, H. (2024) · Rinsho Shinkeigaku · doi:10.5692/clinicalneurol.cn-001924 · Cited by 3
Leber hereditary optic neuropathy in Slovenia: quality of life and costs from patient perspective
Hawlina, M., Kovač, L., Breciková, K., Zigmond, J., Rogalewicz, V., Tichopád, A., Višňanský, M., & Šarkanová, I. (2024) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-024-03329-0 · Cited by 2
“Idebenone, a synthetic version of coenzyme Q10, is the primary treatment option approved for LHON patients [13].”
BackgroundA Review over Mitochondrial Diseases Due to mtDNA Mutations: Recent Advances and Remedial Aspects
Bharadwaj, A. (2024) · Infectious Disorders - Drug Targets · doi:10.2174/0118715265304029240801092834 · Cited by 2
Cascade testing in mitochondrial diseases: a cross-sectional retrospective study
Haque, S., Crawley, K., SCHOFIELD, D. J., Shrestha, R. N., & Sue, C. M. (2024) · BMC Neurology · doi:10.1186/s12883-024-03850-6 · Cited by 2
“…in ‘current standards’ or becoming increasingly recognised) in mitochondrial diseases include Idebenone for Leber’s Hereditary Optic Neuropathy [33, 34] and L-arginine [35, 36] administration for stroke-like episodes in Mitochondrial Encepha-lomyopathy, Lactic Acidosis and Stroke-like episodes…”
BackgroundHalawani, M. A., & Badeeb, N. O. (2025) · American Journal of Ophthalmology Case Reports · doi:10.1016/j.ajoc.2025.102346 · Cited by 2
“57 A 2020 study showed that Idebenone holds the potential to promote visual acuity stabilization and possibly recovery in patients with ADOA.”
Xhuti, D., Chiarot, A., Minhas, M., Tobia, S., de Maat, N. M., Manta, K., Ng, S. Y., Tarnopolsky, M. A., & Nederveen, J. P. (2025) · Human Molecular Genetics · doi:10.1093/hmg/ddaf125 · Cited by 3
Das Deutsche Netzwerk für mitochondriale Erkrankungen (mitoNET)
Büchner, B., Gallenmüller, C., Lautenschläger, R., Kuhn, K. A., Wittig, I., Schöls, L. J., Rapaport, D., Seelow, D., Freisinger, P., Prokisch, H., et al. (2012) · Medizinische Genetik · doi:10.1007/s11825-012-0338-8 · Cited by 2
Self-citationEn tenåring med akutt bilateralt synstap
Ødegaard, E. M., Jørstad, Ø. K., & Kerty, E. (2018) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.17.0802 · Cited by 2
An uncommon cause of vision loss: Leber hereditary optic neuropathy
Glover, J. M., Casmaer, M. L., & April, M. D. (2018) · JAAPA · doi:10.1097/01.jaa.0000546478.56818.50 · Cited by 3
Mitochondrial Optic Neuropathies
Carelli, V., Morgia, C. L., & Klopstock, T. (2019) · Springer eBooks · doi:10.1007/978-3-030-05517-2_8 · Cited by 2
Self-citationNewer Techniques in Vision Restoration and Rehabilitation
Hanson, K., Lewerenz, D., & Subramanian, P. S. (2019) · Current practices in ophthalmology · doi:10.1007/978-981-13-9795-0_9 · Cited by 2
Les maladies mitochondriales de l’adulte : mise au point
Allouche, S., Schaeffer, S., & Chapon, F. (2021) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2020.12.002 · Cited by 4
Bioactivity Profiles of Cytoprotective Short-Chain Quinones
Feng, Z., Nadikudi, M., Woolley, K. L., Hemasa, A. L., Chear, S., Smith, J. A., & Gueven, N. (2021) · Molecules · doi:10.3390/molecules26051382 · Cited by 2
Dmitry, P. I. (2021) · Studies in natural products chemistry · doi:10.1016/b978-0-12-819487-4.00018-5 · Cited by 3
Mitochondriale Erkrankungen – Ein Update zu Klinik, Diagnostik und Therapie
Stendel, C., Neuhofer, C. M., & Klopstock, T. (2022) · Neurologie up2date · doi:10.1055/a-1514-2141 · Cited by 2
Self-citationStendel, C., & Klopstock, T. (2016) · InFo Neurologie + Psychiatrie · doi:10.1007/s15005-016-1783-8 · Cited by 2
Self-citationInherited Optic Neuropathies: Real-World Experience in the Paediatric Neuro-Ophthalmology Clinic
Gilhooley, M. J., Raoof, N., Yu‐Wai‐Man, P., & Moosajee, M. (2024) · Genes · doi:10.3390/genes15020188 · Cited by 2
“Both simplex and syndromic inherited optic neuropathies have traditionally been linked by a lack of treatment options; however, drugs, including idebenone [12,13], and nascent gene therapies—particularly gene replacement therapies—such as GS010 for LHON [14] have come to the fore in recent years.”
BackgroundSelf-citationAhmad, K. E., Fraser, C. L., Sue, C. M., & Barton, J. J. S. (2016) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2016.02.003 · Cited by 2
Current biochemical treatments of mitochondrial respiratory chain disorders
Heaton, R. A., Millichap, L. E., Saleem, F., Gannon, J., Begum, G., & Hargreaves, I. P. (2019) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2019.1638250 · Cited by 2
Case 21-2019: A 31-Year-Old Woman with Vision Loss
Matiello, M., Juliano, A. F. T., Bowley, M. P., & Karaa, A. (2019) · New England Journal of Medicine · doi:10.1056/nejmcpc1900597 · Cited by 2
Mackey, D. A., & Kearns, L. S. (2019) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.13586 · Cited by 2
“Idebenone showed initial promise with a single case of the 11 778 LHON mutation,(4) but later reports were mixed, leading to a randomized clinical trial that was not really conclusive as to the efficacy of idebenone.(5) A major problem with LHON is the well documented natural history of partial visual recovery without…”
ResultMitochondrial Transplantation in the Eye: A Review and Evaluation of Surgical ApproachesPreprint
Cakir, B., Yeh, T.-C., Lin, C., Wu, M.-R., Boilard, É., Pelletier, M., Singh, A., Breton, Y., Patel, S. P., Benson, T., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.06.716722 · Cited by 4
Turton, N., Rutherford, T., Thijssen, D. H. J., & Hargreaves, I. P. (2020) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2020.1850254 · Cited by 1
Kumar, S., Choudhary, N., Faruq, M., Kumar, A., Saran, R. K., Indercanti, P. K., Singh, V., Sait, H., Jaitley, S., Vališ, M., et al. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2176927 · Cited by 2
Chen, Y., & Kellom, E. R. (2023) · American Journal of Ophthalmology Case Reports · doi:10.1016/j.ajoc.2023.101936 · Cited by 1
“5,6 The apparent female predominance in our cohort could have been attributed to the lack of male relatives in the family.”
BackgroundWang, D., Yuan, J., Liu, H., Li, S. W., Ma, N., Chen, M.-L., Yuan, H., Jie, H., Li, B., & Zhang, T. (2024) · BMC Ophthalmology · doi:10.1186/s12886-024-03625-0 · Cited by 1
Ozir, M. A., Nordin, M. H., Hashim, S. E., Adzahar, S., Ahmad, M. A., Ng, K. S., & Hitam, W. H. W. (2024) · Cureus · doi:10.7759/cureus.71210 · Cited by 1
Advances in research on Leber's hereditary optic neuropathy
Zhou, Q., Liu, Z., Sun, J., Lü, L., Han, E., & Zhang, L. (2024) · Ocular genetics and omics. · doi:10.1016/j.ogo.2024.100002 · Cited by 4
Metadata
- Authors
- Klopstock, T., Yu-Wai-Man, P., Dimitriadis, K., Rouleau, J., Heck, S., Bailie, M., Atawan, A., Chattopadhyay, S., Schubert, M., Garip, A., Kernt, M., Petraki, D., Rummey, C., Leinonen, M., Metz, G., Griffiths, P. G., Meier, T., & Chinnery, P. F.
- Affiliations
- Ludwig-Maximilians-Universität München (DE)
- 2 Department of Neurology, Royal Victoria Infirmary, Newcastle upon Tyne Foundation Hospital, NE1 4LP, NHS Trust, UK
- Centre Hospitalier de l’Université de Montréal (CA)
- Royal Victoria Infirmary (GB)
- Santhera Pharmaceuticals (Switzerland) (CH)
- 8 4Pharma, Stockholm, 16440 Kista, Sweden
- Corresponding author
- Chinnery, Patrick F.
- ORCID
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-07-23
- Volume
- 134
- Issue
- 9
- Pages
- 2677-2686
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC3170530
- OpenAlex
- W2124154990
- Cited by
- 578
- References
- 32
- Citations by year
- 2026: 25 · 2025: 35 · 2024: 41 · 2023: 36 · 2022: 44 · 2021: 42 · 2020: 69 · 2019: 39 · 2018: 31 · 2017: 28 · 2016: 61 · 2015: 28 · 2014: 28 · 2013: 29 · 2012: 29
- FWCI
- 16.96
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Brain (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- Wellcome Trust (01GM0862)
- National Institute for Health and Care Research (NF-SI-0509-10011)
- Parkinson's UK
- Deutsche Forschungsgemeinschaft
- Bundesministerium für Bildung und Forschung (01GM0862)
- Medical Research Council
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroprotection in Cerebral Ischemia
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
- Health Sciences › Medicine › Ophthalmology › Glaucoma and retinal disorders
- Keywords
- idebenone, Leber's hereditary optic neuropathy, mitochondrial DNA mutations, mitochondrial disease, visual acuity, retinal nerve fiber layer thickness, treatment response heterogeneity, drug safety and tolerability
- MeSH terms
- Adolescent, Adult, Aged, Antioxidants, DNA, Mitochondrial, Double-Blind Method, Female, Humans, Male, Middle Aged, Mutation, Placebos, Prospective Studies, Retina, Ubiquinone, Visual Acuity, Contrast Sensitivity, Optic Atrophy, Hereditary, Leber, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.